A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
A phase 2 trial of PM8002 in neuroendocrine tumours, run by Biotheus Inc., active and no longer recruiting.
Overview
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN is a phase 2 interventional study registered as NCT05879055 by Biotheus Inc., with 31 participants enrolled, started 2023-05-17 and due to reach its primary completion in 2027-01-01. Interventions recorded: PM8002 and FOLFIRI.
Setting
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm
Phase
Phase 2
Sponsor
Biotheus Inc.
Registry
Enrolled
31
Similar pages
not linked directly; found by shared links- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- TrialA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
- TrialA Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- TrialFirst-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors